GRI Bio, Inc. Share Price & Technical Analysis
GRI · $2.06 (-7.21%)
Healthcare / Biotechnology
$2.06
-7.21%
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung d…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-5% return in May, -23% avg return in past 3 year May month.
-96% return in 2026, -217% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -53% | -22% | -8% | -8% | -5% | – | – | – | – | – | – | – | -96% |
| 25 | -25% | -22% | -57% | -80% | -25% | -1% | 1% | 7% | 49% | -17% | 18% | -87% | -241% |
| 24 | -35% | -55% | -8% | -45% | -29% | -51% | -60% | -35% | -28% | 143% | -27% | 25% | -204% |
| 23 | -5% | 73% | -20% | -36% | -14% | -27% | -22% | -65% | 15% | -24% | -48% | -36% | -207% |
| 22 | -19% | 54% | -74% | -35% | -53% | 7% | -41% | 5% | -30% | -18% | -5% | 21% | -187% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.24M
P/E ratio
—
52W high
$80.36
52W low
$1.97
Volume
29,576
Beta
-0.77
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is GRI Bio, Inc. share price today?
- GRI Bio, Inc. (GRI) last traded around $2.06 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GRI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GRI. Download the app for real-time alerts.
- How can I analyze GRI Bio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.